MML Investors Services
ADMA icon

MML Investors Services’s ADMA Biologics ADMA Stock Holding History

MML Investors Services’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-42,104
Closed -$379K – 3255
2026
Q1 		$379K Buy
42,104
+13,052
+45% +$206K ﹤0.01% 2399
2025
Q4 		$530K Buy
29,052
+3,829
+15% +$64.5K ﹤0.01% 2230
2025
Q3 		$370K Buy
+25,223
New +$432K ﹤0.01% 2374

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

MML Investors Services's ADMA Position: Q2 2026 in Review

MML Investors Services sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 42,104 shares — an estimated $379K sold.

MML Investors Services first reported a position in ADMA in Q3 2025 and held it in 3 quarters. The position peaked at $530K in Q4 2025. 240 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • MML Investors Services reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • MML Investors Services sold 42,104 ADMA Biologics shares in Q2 2026, an estimated $379K.
  • MML Investors Services first reported a position in ADMA Biologics in Q3 2025 and held it in 3 quarters.
  • MML Investors Services's ADMA Biologics position peaked at $530K in Q4 2025.
  • 240 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on MML Investors Services's 13F filing for Q2 2026, filed 7 Aug 2026.